{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:11:05Z","timestamp":1779376265168,"version":"3.53.1"},"reference-count":35,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Veterinary Medicine &amp;amp; Sci"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Methicillin\u2010resistant\n                      <jats:italic>Staphylococcus pseudintermedius<\/jats:italic>\n                      (MRSP) is an important veterinary pathogen. In general, only a few antimicrobials show in vitro activity against MRSP isolates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The objective of this study was to determine the in vitro activity of selected antimicrobials, including last\u2010choice drugs, against clinical MRSP isolates of canine origin. The activity of 10 selected agents was evaluated against 41 clinical MRSP isolates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The disk diffusion method and minimal inhibitory concentration values were used for antimicrobial susceptibility testing (AST). The guidelines for staphylococci of canine or human origin were employed for the interpretation of the results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the examined MRSP isolates, resistance to enrofloxacin and clindamycin was the most prevalent (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a040; 97.6%). Resistance to doxycycline and gentamicin was observed in 83.0% (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a034) and 68.3% (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a028) of the isolates, respectively. Single isolates were resistant to chloramphenicol (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a05; 12.2%) and rifampicin (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a03; 7.3%), whereas all showed susceptibility to amikacin, vancomycin, mupirocin and linezolid. Predominantly, the results of AST obtained by both methods were consistent. Some discrepancies were observed for gentamicin; however, clinical breakpoints for staphylococci of human origin were used.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Amikacin and chloramphenicol constitute potential treatment options in infections caused by MRSP and may be included in extended susceptibility testing in our geographical region. The determination of clinical breakpoints for some antimicrobials not incorporated in the recommendations should be a high priority in the veterinary diagnostics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/vms3.1385","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T13:41:49Z","timestamp":1711633309000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["In vitro activity of selected antimicrobials against methicillin\u2010resistant\n                    <i>Staphylococcus pseudintermedius<\/i>\n                    of canine origin in Poland"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-4645","authenticated-orcid":false,"given":"Magdalena","family":"Kizerwetter\u2010\u015awida","sequence":"first","affiliation":[{"name":"Department of Preclinical Sciences Institute of Veterinary Medicine Warsaw University of Life Sciences  Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Chrobak\u2010Chmiel","sequence":"additional","affiliation":[{"name":"Department of Preclinical Sciences Institute of Veterinary Medicine Warsaw University of Life Sciences  Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Stefa\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Preclinical Sciences Institute of Veterinary Medicine Warsaw University of Life Sciences  Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Kwiecie\u0144","sequence":"additional","affiliation":[{"name":"Department of Preclinical Sciences Institute of Veterinary Medicine Warsaw University of Life Sciences  Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Rzewuska","sequence":"additional","affiliation":[{"name":"Department of Preclinical Sciences Institute of Veterinary Medicine Warsaw University of Life Sciences  Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,3,28]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11121758"},{"key":"e_1_2_13_3_1","volume-title":"Performance standards for antimicrobial disk susceptibility tests, M02","author":"Clinical and Laboratory Standards Institute","year":"2018"},{"key":"e_1_2_13_4_1","volume-title":"Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals","author":"Clinical and Laboratory Standards Institute","year":"2020"},{"key":"e_1_2_13_5_1","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). (2023).Breakpoint tables for interpretation of MICs and zone diameters.EUCAST.http:\/\/www.eucast.org"},{"key":"e_1_2_13_6_1","unstructured":"European Medicines Agency (EMA). (2018).Reflection paper on off\u2010label use of antimicrobials in veterinary medicine in the European Union.European Medicines Agency. Accessed 22 June 2023.https:\/\/www.ema.europa.eu\/documents\/scientific\u2010guideline\/reflection\u2010paper\u2010label\u2010use\u2010antimicrobials\u2010veterinary\u2010medicine\u2010european\u2010union\u2010first\u2010version_en.pdf"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12917\u2010019\u20101990\u2010x"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12118"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2020.00414"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr118"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2016.04.015"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/1348\u20100421.12401"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2021.109160"},{"key":"e_1_2_13_14_1","unstructured":"Kohn M. A. &Senyak J.(2021).Sample size calculators.UCSF CTSI.https:\/\/www.sample\u2010size.net\/"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2018.04.002"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/vetsci8010011"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469\u20100691.2011.03570.x"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cimid.2019.101331"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2014.02.008"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1167834"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12444"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2021.109119"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.12921"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.23.01.0023"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq078"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cimid.2023.102028"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.01599"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.13005"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2010.01.008"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01232\u201009"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411361"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.9.4089\u20104094.2003"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02572\u201020"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0269422"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2018.09.013"},{"key":"e_1_2_13_36_1","unstructured":"World Health Organization (WHO). (2019).Critically important antimicrobials for human medicine 6th revisionGeneva.WHOhttp:\/\/apps.who.int\/ir"}],"container-title":["Veterinary Medicine and Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/vms3.1385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T03:41:52Z","timestamp":1717990912000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/vms3.1385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,28]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1002\/vms3.1385"],"URL":"https:\/\/doi.org\/10.1002\/vms3.1385","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/VMS3.1385\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/VMS3.1385\/v3\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/VMS3.1385\/v3\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/VMS3.1385\/v4\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/VMS3.1385\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/VMS3.1385\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/VMS3.1385\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/VMS3.1385\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/VMS3.1385\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/VMS3.1385\/v4\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/VMS3.1385\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/VMS3.1385\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/VMS3.1385\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/VMS3.1385\/v4\/response1","asserted-by":"object"}]},"ISSN":["2053-1095","2053-1095"],"issn-type":[{"value":"2053-1095","type":"print"},{"value":"2053-1095","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,28]]},"assertion":[{"value":"2023-07-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1385"}}